NAECB Asthma Medication 2

Question 1

Which inhaled corticosteroid (ICS) is approved for use in children as young as 12 months for asthma maintenance?

Accepted Answer

Budesonide (Pulmicort Respules)

Answer

Budesonide (Pulmicort Respules) is approved for children 12 months to 8 years via nebulizer.

Question 2

A patient on high-dose ICS plus LABA still has uncontrolled asthma. Which biologic targets IL-5 to reduce eosinophil levels?

Accepted Answer

Mepolizumab (Nucala)

Answer

Mepolizumab (Nucala) is an anti-IL-5 monoclonal antibody that reduces eosinophil production.

Question 3

What is the recommended maximum daily dose of albuterol (levalbuterol excluded) via MDI for an adult with acute asthma exacerbation in the ED?

Accepted Answer

2 puffs every 20 minutes for 3 doses

Answer

In acute exacerbations, albuterol MDI is typically dosed as 2–4 puffs every 20 minutes for 3 doses (first hour).

Question 4

Which leukotriene receptor antagonist (LTRA) is approved for both asthma and allergic rhinitis in patients as young as 6 months?

Accepted Answer

Montelukast (Singulair)

Answer

Montelukast is approved for perennial allergic rhinitis in patients ≥6 months and asthma in patients ≥1 year.

Question 5

A patient using a spacer with MDI has poor technique. Which error MOST reduces drug delivery to the lungs?

Accepted Answer

Actuating the inhaler before beginning to inhale

Answer

Actuating the inhaler before inhaling causes most drug to deposit in the spacer walls rather than reaching the lungs.

NAECB Exam Practice Test